At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1 enrolled
Drug / intervention
Atalurendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label N of 1 Study to Evaluate the Study and Efficacy of Long-Term Treatment With Ivacaftor in Combination With Ataluren (PTC124) in Subjects With Nonsense Mutation Cystic Fibrosis
In Brief
A Phase 4 clinical trial evaluating Ataluren for Cystic Fibrosis. Completed, enrolled 1 participant across 1 site.
Detailed Summary
The purpose of this study is to explore the combination of ataluren and ivacaftor as a treatment for patients with nonsense mutation cystic fibrosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedAug 2017
Primary CompletionDec 2018
Study CompletionDec 2018
TodayJul 2026
First PostedAug 22, 2017
Enrollment StartJan 27, 2017
Primary CompletionDec 1, 2018
Study CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.9 years ago
Interventions
Atalurendrug
ataluren